Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Robert Herman Vonderheide, MD, DPhil

Robert Herman Vonderheide, MD, DPhil Physician

Director of the Abramson Cancer Center John H. Glick Abramson Cancer Center Professor

Dr. Vonderheide is employed by Penn Medicine.

Request an Appointment

Not accepting new patients

No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.
X

About Dr. Robert H. Vonderheide

Dr. Vonderheide is an internationally renowned cancer immunotherapy and translational research expert.  Through a focus on novel immunotherapies for pancreatic cancer, melanoma and breast cancers, Dr. Vonderheide has mapped new models for speeding translational - or "bench to bedside" research.  He is currently the Director of the Abramson Cancer Center.

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 2000

Clinical Expertise:

  • Pancreatic Cancer

Description of Clinical Expertise

Medical Oncology and Experimental Therapeutics, in particular Immunotherapy

Practice Locations and Appointments

  • Abramson Cancer Center

    Perelman Center for Advanced Medicine West Pavilion, 2nd Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-7366 (PENN)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Harvard University
Residency: Massachusetts General Hospital
Fellowship: Dana-Farber Cancer Institute

Memberships

American Association of Cancer Research Cancer Immunology Working Group, National American Association of Cancer Research, National American Association of Physicians, National American Society of Clinical Investigation, National American Society of Clinical Oncology, National Cancer Immunotherapy Trials Network, National Cancer Institute, National Immunotherapy Task Force, Investigation Drug Steering Committee, National Cancer Institute, National Lustgarten Foundation for Pancreatic Cancer, National National Institutes of Health (Dallas, TX), National National Institutes of Health (Denver, CO), National National Institutes of Health, Cancer Immunopathology and Immunotherapy Study Section, National Pancreatic Cancer Action Network, National Society for Immunotherapy of Cancer , National

Hospital Affiliation

Dr. Vonderheide is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

RESEARCH INTERESTS
The Vonderheide laboratory combines efforts in both basic research and clinical investigation to advance the understanding of tumor immunology and to develop novel immunotherapies for cancer. The chief hypothesis is that successful approaches in tumor immunotherapy will need to (a) optimize target antigens with regard to clinical applicability and risk of antigen loss, (b) repair host immuno-incompetence in antigen presentation and T cell function, and (c) circumvent immuno-suppressive factors of the tumor and tumor microenvironment.

RESEARCH DETAILS
Dr. Vonderheide’s basic research includes deciphering the immunobiology of novel genetically engineered mouse models of cancer, including the regulation of immune surveillance and the tumor microenvironment by CD40 and other pathways, and with a focus on pancreatic cancer, breast cancer, and melanoma. His translational work tests novel approaches such as vaccines, antibodies, and adoptive T cells for the treatment of patients with melanoma, pancreatic cancer and other cancers. He has studied ‘universal’ tumor antigens, immune effects of radiation, and immune modulatory pathways involving CD40, GM-CSF, PD-1, CTLA-4, and CD25. Publications include those in high-impact journals such as Nature, Science, Cell, and the New England Journal of Medicine.


LABORATORY PERSONNEL
Robert Vonderheide, MD, DPhil
Director, Abramson Cancer Center; John H. Glick MD Abramson Cancer Center's Professor

Nune Markosyan, MD, PhD, Laboratory Director

Katelyn Byrne, PhD, Instructor in Medicine

Mark Diamond, MD, PhD, Instructor in Medicine

Adham Bear, MD, PhD, Clinical Fellow

Alex Morrison, MD, TRM Student

Bereket Gebregziabher, undergraduate student

Ceire Hay, research specialist

Austin Huffman, Graduate Student (PhD, Immunology)

Jeffrey Lin, Graduate Student (MD/PhD)

Liz Quinones, research specialist

Andrew Rech, Post-doctoral Scholar (MD/PhD)

Lee Richman, Graduate Student (MD/PhD)

Mark Sudell, Administrator, 215-746-8901; msudell@mail.med.upenn.edu








Selected Publications:

Bajor David L, Xu Xiaowei, Torigian Drew A, Mick Rosemarie, Garcia Laura R, Richman Lee P, Desmarais Cindy, Nathanson Katherine L, Schuchter Lynn M, Kalos Michael: Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma. Cancer immunology research 2 (11): 1051-8,2014.

Condamine Thomas, Kumar Vinit, Ramachandran Indu R, Youn Je-In, Celis Esteban, Finnberg Niklas, El-Deiry Wafik S, Winograd Rafael, Vonderheide Robert H, English Nickolas R, Knight Stella C, Yagita Hideo, McCaffrey Judith C, Antonia Scott, Hockstein Neil, Witt Robert, Masters Gregory, Bauer Thomas: ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. The Journal of clinical investigation 124 (6): 2626-39,2014.

Zhang Yaqing, Yan Wei, Mathew Esha, Bednar Filip, Wan Shanshan, Collins Meredith A, Evans Rebecca A, Welling Theodore H, Vonderheide Robert H: CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice. Cancer immunology research 2 (5): 423-35,2014.

Richman Lee P: Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer immunology research 2 (1): 19-26,2014.

Mueller Christian, Chulay Jeffrey D, Trapnell Bruce C, Humphries Margaret, Carey Brenna, Sandhaus Robert A, McElvaney Noel G, Messina Louis, Tang Qiushi, Rouhani Farshid N, Campbell-Thompson Martha, Fu Ann Dongtao, Yachnis Anthony, Knop David R, Ye Guo-Jie, Brantly Mark, Calcedo Roberto, Somanathan Suryanarayan, Richman Lee P, Vonderheide Robert H, Hulme Maigan A, Brusko Todd M, Wilson James M: Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. The Journal of clinical investigation 123 (12): 5310-8,2013.

Markosyan N, Chen EP, Evans RA, Ndong V, Vonderheide RH: Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity. Breast Cancer Research 15 (5): R75 [Epub ahead of print],2013.

Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH: A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clinical Cancer Research : [Epub ahead of print],2013.

Bayne LJ: A myeloid-derived suppressor cell-mediated T-cell suppression assay for functional evaluation of immune cells in tumor-bearing mice. Cold Spring Harb Protoc. 2013 (9): 2013.

Vonderheide RH,Burg JM, Mick R, Trosko JA, Li D, Shaik MN, Tolcher AW: Phase I study of CD40 antibody CP-870,893 in combination with carboplatin and paclitaxel in patients with advanced solid tumors OncoImmunology 2 : e23033,2013.

Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vonderheide RH, Albelda SM, June CH: Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Can Res Treat 133 : 799-804,2012.

View all publications

Academic Contact Info

12 South Pavilion
3400 Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 662-3929
Patient appointments: 800-789-7366 (PENN)